Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study.
Agustín Sancho-SaldañaAnna Gil-SánchezCristina González-MingotSilvia PeraltaMaria Jose SolanaPascual TorresAlba JuanesLaura QuibusEmilio RuizEduardo SanpedroBibiana Quirant-SanchezEva Martínez-CáceresCristina Ramo TelloSilvia Presas-RodríguezSebatián García RubioBeatriz Pardiñas BaronLluis Ramio-TorrentàJavier SotocaInés González-SuárezSara EichauJosé María Prieto-GonzálezMaria Rosario Blasco QuilezJulia Sabín-MuñozAntonio José Sánchez-LópezGloria Llorens CalatayudCarmen CallesÁngel Pérez SempereMoises GarcésOlga Carmona I CodinaEster MoralJosé Vicente HervásYolanda BlancoNuria Sola-VallsNieves Tellez LaraLucía ForeroLuis BrievaPublished in: Journal of clinical medicine (2023)
pwMS undergoing DMTs exhibited a higher seroprevalence of COVID-19 than the general population. Interferon treatment was associated with a higher seroprevalence, suggesting a more robust humoral response. This study provides valuable insights into the seroprevalence and persistence of SARS-CoV-2 antibodies in pwMS and contributes to our understanding of the impact of COVID-19 amongst this population.